What question did this study set out to answer?

The aim is to formulate and characterize lipid-based nanocarriers for controlled release of ciprofloxacin.

June 19, 2026PharmaceuticsOpen Access

Systematic Study of Ciprofloxacin Release from Lipid-Based Nanocarriers

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates ciprofloxacin release in lipid-based nanocarriers, suggesting enhanced control over drug delivery.

The aim is to formulate and characterize lipid-based nanocarriers for controlled release of ciprofloxacin.
Formulated solid lipid nanoparticles and nanostructured lipid carriers for ciprofloxacin delivery.
Characterized using dynamic light scattering, transmission electron microscopy, and atomic force microscopy.
Conducted in vitro release studies and applied mathematical modeling for release kinetics analysis.
SLN 50 had an average size of ~50 nm and high encapsulation efficiency (~98%).
NLC 25 released ~95% within 30 min, while NLC 100 showed <20% after 6 h, indicating size impact on release kinetics.
Dissolution profiles fit the Lumped-Gonzo kinetic model with R2 > 0.98.

Arrúa et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark